tiprankstipranks
10X Genomics (DE:1KJ)
NASDAQ:1KJ
Germany Market
1KJ
10x Genomics
RESEARCH TOOLSreports

10x Genomics (1KJ) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

1KJ Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
3 Buy
7 Hold
0 Sell
Based on 10 analysts giving stock ratings to
10x
Genomics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1KJ Stock 12 Month Forecast

Average Price Target

€22.64
▲(6.37% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for 10x Genomics in the last 3 months. The average price target is €22.64 with a high forecast of €35.16 and a low forecast of €17.58. The average price target represents a 6.37% change from the last price of €21.28.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","36":"€36","14.25":"€14.25","21.5":"€21.5","28.75":"€28.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.1619912,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€35.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.635531835,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€22.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.5809956,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,14.25,21.5,28.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.865,25.657076246153846,26.449152492307693,27.241228738461537,28.033304984615384,28.82538123076923,29.61745747692308,30.409533723076926,31.20160996923077,31.993686215384617,32.78576246153846,33.57783870769231,34.369914953846155,{"y":35.1619912,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.865,24.693502448846154,24.522004897692305,24.35050734653846,24.179009795384612,24.007512244230767,23.836014693076923,23.664517141923074,23.49301959076923,23.321522039615385,23.150024488461536,22.97852693730769,22.807029386153843,{"y":22.635531835,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.865,24.304691969230767,23.74438393846154,23.184075907692307,22.623767876923075,22.063459846153847,21.503151815384616,20.942843784615384,20.382535753846156,19.822227723076924,19.261919692307693,18.701611661538465,18.141303630769233,{"y":17.5809956,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.398,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.614,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.445,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.76,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.702,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.995,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.355,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.51,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.18,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.555,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.018,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.865,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€35.16Average Price Target€22.64Lowest Price Target€17.58
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:1KJ
Luke Sergott
Barclays
Barclays
€26.37→€35.16
Buy
65.23%
Upside
Assigned
06/24/26
Barclays Reaffirms Their Buy Rating on 10x Genomics (TXG)
Canaccord Genuity Analyst forecast on DE:1KJ
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
€28.13
Buy
32.19%
Upside
Reiterated
06/10/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG), Zevra Therapeutics (NASDAQ: ZVRA) and Merck & Company (NYSE: MRK)
Bank of America Securities Analyst forecast on DE:1KJ
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Hold
―
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG) and Solventum Corporation (NYSE: SOLV)
J.P. Morgan Analyst forecast on DE:1KJ
Casey Woodring
J.P. Morgan
J.P. Morgan
€14.94→€17.58
Hold
-17.38%
Downside
Reiterated
05/12/26
10x Genomics price target raised to $20 from $17 at JPMorgan10x Genomics price target raised to $20 from $17 at JPMorgan
Morgan Stanley Analyst forecast on DE:1KJ
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
€17.58→€19.34
Hold
-9.12%
Downside
Reiterated
05/12/26
10x Genomics price target raised to $22 from $20 at Morgan Stanley10x Genomics price target raised to $22 from $20 at Morgan Stanley
Piper Sandler Analyst forecast on DE:1KJ
David Westenberg
Piper Sandler
Piper Sandler
€16.7→€17.58
Hold
-17.38%
Downside
Reiterated
05/08/26
Piper Sandler Keeps Their Hold Rating on 10x Genomics (TXG)
William Blair Analyst forecast on DE:1KJ
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
05/08/26
10x Genomics: Buy Rating Reaffirmed on Strong Q1, Atera-Driven Growth Outlook, and Attractive Valuation
Deutsche Bank Analyst forecast on DE:1KJ
Justin Bowers
Deutsche Bank
Deutsche Bank
€14.94→€20.22
Hold
-4.99%
Downside
Reiterated
05/08/26
10x Genomics price target raised to $23 from $17 at Deutsche Bank10x Genomics price target raised to $23 from $17 at Deutsche Bank
TD Cowen Analyst forecast on DE:1KJ
Daniel Brennan
TD Cowen
TD Cowen
€16.7→€21.98
Hold
3.27%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG) and Telix Pharmaceuticals (Other OTC: TLPPF)
Citi Analyst forecast on DE:1KJ
Patrick B Donnelly
Citi
Citi
€21.1
Hold
-0.86%
Downside
Assigned
04/07/26
10x Genomics price target raised to $24 from $18 at Citi10x Genomics price target raised to $24 from $18 at Citi
Stifel Nicolaus Analyst forecast on DE:1KJ
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
€17.58→€21.98
Buy
3.27%
Upside
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG), Ascendis Pharma (NASDAQ: ASND) and Roche Holding AG (Other OTC: RHHVF)
RBC Capital Analyst forecast on DE:1KJ
Dan Leonard
RBC Capital
RBC Capital
€12.31→€17.58
Hold
-17.38%
Downside
Reiterated
02/19/26
UBS Reaffirms Their Hold Rating on 10x Genomics (TXG)
Jefferies Analyst forecast on DE:1KJ
Tycho Peterson
Jefferies
Jefferies
€18.46
Buy
-13.25%
Downside
Reiterated
02/13/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (NASDAQ: VRTX) and 10x Genomics (NASDAQ: TXG)
Leerink Partners Analyst forecast on DE:1KJ
Puneet Souda
Leerink Partners
Leerink Partners
€13.19→€14.06
Hold
-33.91%
Downside
Reiterated
08/11/25
Leerink Partners Remains a Hold on 10x Genomics (TXG)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:1KJ
Luke Sergott
Barclays
Barclays
€26.37→€35.16
Buy
65.23%
Upside
Assigned
06/24/26
Barclays Reaffirms Their Buy Rating on 10x Genomics (TXG)
Canaccord Genuity Analyst forecast on DE:1KJ
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
€28.13
Buy
32.19%
Upside
Reiterated
06/10/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG), Zevra Therapeutics (NASDAQ: ZVRA) and Merck & Company (NYSE: MRK)
Bank of America Securities Analyst forecast on DE:1KJ
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Hold
―
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG) and Solventum Corporation (NYSE: SOLV)
J.P. Morgan Analyst forecast on DE:1KJ
Casey Woodring
J.P. Morgan
J.P. Morgan
€14.94→€17.58
Hold
-17.38%
Downside
Reiterated
05/12/26
10x Genomics price target raised to $20 from $17 at JPMorgan10x Genomics price target raised to $20 from $17 at JPMorgan
Morgan Stanley Analyst forecast on DE:1KJ
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
€17.58→€19.34
Hold
-9.12%
Downside
Reiterated
05/12/26
10x Genomics price target raised to $22 from $20 at Morgan Stanley10x Genomics price target raised to $22 from $20 at Morgan Stanley
Piper Sandler Analyst forecast on DE:1KJ
David Westenberg
Piper Sandler
Piper Sandler
€16.7→€17.58
Hold
-17.38%
Downside
Reiterated
05/08/26
Piper Sandler Keeps Their Hold Rating on 10x Genomics (TXG)
William Blair Analyst forecast on DE:1KJ
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
05/08/26
10x Genomics: Buy Rating Reaffirmed on Strong Q1, Atera-Driven Growth Outlook, and Attractive Valuation
Deutsche Bank Analyst forecast on DE:1KJ
Justin Bowers
Deutsche Bank
Deutsche Bank
€14.94→€20.22
Hold
-4.99%
Downside
Reiterated
05/08/26
10x Genomics price target raised to $23 from $17 at Deutsche Bank10x Genomics price target raised to $23 from $17 at Deutsche Bank
TD Cowen Analyst forecast on DE:1KJ
Daniel Brennan
TD Cowen
TD Cowen
€16.7→€21.98
Hold
3.27%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG) and Telix Pharmaceuticals (Other OTC: TLPPF)
Citi Analyst forecast on DE:1KJ
Patrick B Donnelly
Citi
Citi
€21.1
Hold
-0.86%
Downside
Assigned
04/07/26
10x Genomics price target raised to $24 from $18 at Citi10x Genomics price target raised to $24 from $18 at Citi
Stifel Nicolaus Analyst forecast on DE:1KJ
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
€17.58→€21.98
Buy
3.27%
Upside
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG), Ascendis Pharma (NASDAQ: ASND) and Roche Holding AG (Other OTC: RHHVF)
RBC Capital Analyst forecast on DE:1KJ
Dan Leonard
RBC Capital
RBC Capital
€12.31→€17.58
Hold
-17.38%
Downside
Reiterated
02/19/26
UBS Reaffirms Their Hold Rating on 10x Genomics (TXG)
Jefferies Analyst forecast on DE:1KJ
Tycho Peterson
Jefferies
Jefferies
€18.46
Buy
-13.25%
Downside
Reiterated
02/13/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (NASDAQ: VRTX) and 10x Genomics (NASDAQ: TXG)
Leerink Partners Analyst forecast on DE:1KJ
Puneet Souda
Leerink Partners
Leerink Partners
€13.19→€14.06
Hold
-33.91%
Downside
Reiterated
08/11/25
Leerink Partners Remains a Hold on 10x Genomics (TXG)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering 10x Genomics

3 Months
Kyle Mikson CFACanaccord Genuity
Success Rate
14/25 ratings generated profit
56%
Average Return
+0.27%
Copying Kyle Mikson CFA's trades and holding each position for 3 Months would result in 56.00% of your transactions generating a profit, with an average return of +0.27% per trade.
1 Year
Daniel AriasStifel Nicolaus
Success Rate
12/23 ratings generated profit
52%
Average Return
+18.43%
Copying Daniel Arias's trades and holding each position for 1 Year would result in 52.17% of your transactions generating a profit, with an average return of +18.43% per trade.
2 Years
Kyle Mikson CFACanaccord Genuity
Success Rate
16/25 ratings generated profit
64%
Average Return
+38.09%
Copying Kyle Mikson CFA's trades and holding each position for 2 Years would result in 64.00% of your transactions generating a profit, with an average return of +38.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1KJ Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
8
8
11
9
10
Hold
18
15
12
11
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
23
23
20
21
In the current month, 1KJ has received 10 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. 1KJ average Analyst price target in the past 3 months is 22.64.
Each month's total comprises the sum of three months' worth of ratings.

1KJ Financial Forecast

1KJ Earnings Forecast

Next quarter’s earnings estimate for 1KJ is -€0.20 with a range of -€0.31 to -€0.03. The previous quarter’s EPS was -€0.09. 1KJ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1KJ has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1KJ is -€0.20 with a range of -€0.31 to -€0.03. The previous quarter’s EPS was -€0.09. 1KJ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1KJ has Performed in-line its overall industry.

1KJ Sales Forecast

Next quarter’s sales forecast for 1KJ is €127.28M with a range of €126.64M to €128.16M. The previous quarter’s sales results were €130.93M. 1KJ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1KJ has Performed in-line its overall industry.
Next quarter’s sales forecast for 1KJ is €127.28M with a range of €126.64M to €128.16M. The previous quarter’s sales results were €130.93M. 1KJ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1KJ has Performed in-line its overall industry.

1KJ Stock Forecast FAQ

What is DE:1KJ’s average 12-month price target, according to analysts?
Based on analyst ratings, 10X Genomics’s 12-month average price target is 22.64.
    What is DE:1KJ’s upside potential, based on the analysts’ average price target?
    10X Genomics has 6.37% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is 10X Genomics a Buy, Sell or Hold?
          10X Genomics has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 7 hold ratings and 0 sell ratings.
            What is 10X Genomics’s share price target?
            The average share price target for 10X Genomics is 22.64. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €35.16 ,and the lowest forecast is €17.58. The average share price target represents 6.37% Increase from the current price of €21.28.
              What do analysts say about 10X Genomics?
              10X Genomics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of 10X Genomics?
                To buy shares of DE:1KJ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.